TY - JOUR
T1 - A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance
AU - Liao, Yuning
AU - Liu, Yuan
AU - Shao, Zhenlong
AU - Xia, Xiaohong
AU - Deng, Yuanfei
AU - Cai, Jianyu
AU - Yao, Leyi
AU - He, Jinchan
AU - Yu, Cuifu
AU - Hu, Tumei
AU - Sun, Wenshuang
AU - Liu, Fang
AU - Tang, Daolin
AU - Liu, Jinbao
AU - Huang, Hongbiao
N1 - Funding Information:
Acknowledgements This work was supported by National Natural Science Foundation of China (82072810, 82002481, 81972399), the Science and Technology Program of Guangzhou (202002030107), projects from Foundation for Higher Education of Guangdong (2019KQNCX113), Special fund of Foshan Summit plan (2019D001), Grant from Foshan Science technology and Medical foundation (1920001000958) and Guangzhou key medical discipline construction project fund.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/6/24
Y1 - 2021/6/24
N2 - Prostate cancer (PC) is the second most common cancer with limited treatment option in males. Although the reactivation of embryonic signals in adult cells is one of the characteristics of cancer, the underlying protein degradation mechanism remains elusive. Here, we show that the molecular chaperone GRP75 is a key player in PC cells by maintaining the protein stability of SIX1, a transcription factor for embryonic development. Mechanistically, GRP75 provides a platform to recruit the deubiquitinating enzyme USP1 to inhibit K48-linked polyubiquitination of SIX1. Structurally, the C-terminus of GRP75 (433-679 aa) contains a peptide binding domain, which is required for the formation of GRP75-USP1-SIX1 protein complex. Functionally, pharmacological or genetic inhibition of the GRP75-USP1-SIX1 protein complex suppresses tumor growth and overcomes the castration resistance of PC cells in vitro and in xenograft mouse models. Clinically, the protein expression of SIX1 in PC tumor tissues is positively correlated with the expression of GRP75 and USP1. These new findings not only enhance our understanding of the protein degradation mechanism, but also may provide a potential way to enhance the anti-cancer activity of androgen suppression therapy.
AB - Prostate cancer (PC) is the second most common cancer with limited treatment option in males. Although the reactivation of embryonic signals in adult cells is one of the characteristics of cancer, the underlying protein degradation mechanism remains elusive. Here, we show that the molecular chaperone GRP75 is a key player in PC cells by maintaining the protein stability of SIX1, a transcription factor for embryonic development. Mechanistically, GRP75 provides a platform to recruit the deubiquitinating enzyme USP1 to inhibit K48-linked polyubiquitination of SIX1. Structurally, the C-terminus of GRP75 (433-679 aa) contains a peptide binding domain, which is required for the formation of GRP75-USP1-SIX1 protein complex. Functionally, pharmacological or genetic inhibition of the GRP75-USP1-SIX1 protein complex suppresses tumor growth and overcomes the castration resistance of PC cells in vitro and in xenograft mouse models. Clinically, the protein expression of SIX1 in PC tumor tissues is positively correlated with the expression of GRP75 and USP1. These new findings not only enhance our understanding of the protein degradation mechanism, but also may provide a potential way to enhance the anti-cancer activity of androgen suppression therapy.
UR - http://www.scopus.com/inward/record.url?scp=85107293143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107293143&partnerID=8YFLogxK
U2 - 10.1038/s41388-021-01851-0
DO - 10.1038/s41388-021-01851-0
M3 - Article
C2 - 34079090
AN - SCOPUS:85107293143
SN - 0950-9232
VL - 40
SP - 4291
EP - 4306
JO - Oncogene
JF - Oncogene
IS - 25
ER -